How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

When the Label Says More Than the Body Needs: A Growing Push to Rethink Cancer Drug Dosing

Activelifezero.com – For decades, the approved dose printed on a prescription label has functioned as an unchallengeable ceiling in American oncology. Oncologists follow it, insurers reimburse it, and patients receive it — even when emerging clinical experience suggests the quantity or duration may be far greater than what a given body actually requires. A quiet but accelerating movement of physicians, researchers, and patients themselves is now pressing for formal studies that would determine whether substantially reduced amounts of certain immunotherapy agents can match the efficacy of full-strength regimens while sparing patients from debilitating toxicity.

A Patient’s Self-Directed Exit from Treatment

The question became personal for Chuck Manski, a Northwestern University economist whose academic specialty is decision-making under uncertainty. In 2022, Manski was diagnosed with advanced melanoma and began receiving monthly intravenous infusions of nivolumab, marketed as Opdivo. Over six months, the therapy delivered its intended immunological effect but also wrecked his thyroid gland — a damage that committed him to lifelong hormone replacement — and produced agonizing dryness across his eyes, lips, and oral mucosa.

The FDA-mandated protocol for nivolumab in that indication called for a full twelve months of treatment. When Manski raised the question of whether continuing was medically necessary, his oncologist offered no pharmacological rationale beyond regulatory compliance.

“It’s FDA-approved, so that’s what we use,” she told him.

By mid-treatment, Manski displayed no residual signs or symptoms of melanoma. After immersing himself in peer-reviewed oncology literature, he reasoned that the severity of his adverse effects signaled the immune system had already been sufficiently activated. He stopped the regimen on his own judgment.

“She couldn’t tell me a year was the optimal dose. Nobody could,” Manski recalled in a June interview conducted from Spain, where he was attending to receive an award recognizing his economics scholarship. “So I made my own diagnosis. I took myself off.”

International Clinicians Already Diverging From U.S. Labels

Manski’s unilateral decision mirrored practices already embedded in oncology departments across Canada, Israel, Sweden, and other nations. There, physicians routinely administer nivolumab and its close cousin pembrolizumab (Keytruda) at reduced quantities, over compressed treatment windows, or at extended intervals between cycles — all departures from the schedules codified in American labeling.

In India, oncology groups reported that doses as low as one-twelfth of the labeled nivolumab amount still produced robust anti-tumor responses across several malignancies. The finding underscores what Manski summarized bluntly:

“There is incredible uncertainty in drug dosing.”

That uncertainty has galvanized an informal coalition of clinicians, academic investigators, and patient advocates who are lobbying for post-approval dose-finding trials. Their argument rests on two pillars: clinical safety (avoiding unnecessary organ damage) and economic sustainability (reducing per-patient drug expenditure).

The Cost Pressure Behind the Push

The financial stakes are not abstract. A recent survey conducted by the Kaiser Family Foundation found that 43 percent of American adults had skipped at least one prescribed medication in the preceding twelve months because of out-of-pocket cost. Separately, a 2022 Vanderbilt University analysis of Medicare beneficiaries revealed that roughly 30 percent of cancer-drug prescriptions were never filled at the pharmacy counter.

One modeling exercise covering 29 high-priced oncology agents estimated that had minimum-necessary dosages been applied across the U.S. system in 2024, aggregate savings would have approached $31 billion. Matthew Goetz, a breast-cancer researcher at the Mayo Clinic Comprehensive Cancer Center, framed the structural problem in economic terms:

“Decisions aren’t always made with the best needs of the patients in mind. The bottom line is another reason.”

Why Drugmakers Have Little Incentive to Lower the Dose

The commercial architecture of oncology pharmacology works against dose reduction. Merck sold nearly $32 billion worth of pembrolizumab in the most recent fiscal year — a figure representing almost half of the company’s total pharmaceutical revenue. Pembrolizumab carries FDA approval for more than forty distinct cancer indications, making it one of the broadest-label agents in modern medicine. Bristol Myers Squibb, meanwhile, collected approximately $10 billion from nivolumab, which operates through a comparable immune-checkpoint mechanism.

Three frequently toxic breast-cancer agents — Ibrance (Pfizer), Verzenio (Eli Lilly), and Kisqali (Novartis) — contributed $4.1 billion, $5.7 billion, and $4.8 billion in revenue respectively. Because pembrolizumab is typically dispensed at a flat dose and nivolumab is sometimes weight-adjusted, any downward revision in prescribed quantity translates directly into lower unit revenue for the manufacturer.

Hospital economics compound the disincentive. Under the federal 340B program, established in 1992 to subsidize care for low-income populations, qualifying hospitals purchase drugs at steep discounts yet bill insurers or patients at higher rates. For Medicare infusions specifically, physicians receive an additional six percent of the drug’s average sales price per administration. Between 2010 and 2024, total cancer-drug revenue flowing to physicians and hospitals swelled from roughly $9 billion to nearly $36 billion, according to industry tracking data.

The Gap in Post-Market Evidence

What is conspicuously absent from this ecosystem is systematic dose-optimization research conducted after a drug reaches the market. Early-phase trials establish safety ceilings and efficacy floors; they rarely explore whether a fraction of the approved dose retains therapeutic value. Once a molecule clears FDA review and enters commercial distribution, the financial incentives of manufacturers, hospital systems, and reimbursement structures align against the question “could less be enough?”

The result is a landscape in which patients like Manski must perform their own pharmacological risk-benefit analysis, often armed with journal articles and a growing sense that the label represents a regulatory artifact rather than a biological optimum. Until formal trials close that evidentiary gap, the tension between what the label permits and what the body tolerates will remain an unresolved variable in American cancer care.